E-viri
Recenzirano
Odprti dostop
-
Liu, Haipeng; Su, Hang; Wang, Fei; Dang, Yifang; Ren, Yijiu; Yin, Shenyi; Lu, Huinan; Zhang, Hang; Wu, Jun; Xu, Zhu; Zheng, Mengge; Gao, Jiani; Cao, Yajuan; Xu, Junfang; Chen, Li; Wu, Xiangyang; Ma, Mingtong; Xu, Long; Wang, Fang; Chen, Jianxia; Su, Chunxia; Wu, Chunyan; Xie, Huikang; Gu, Jijie; Xi, Jianzhong Jeff; Ge, Baoxue; Fei, Yiyan; Chen, Chang
Cell reports (Cambridge), 03/2023, Letnik: 42, Številka: 3Journal Article
Enhancing chemosensitivity is one of the largest unmet medical needs in cancer therapy. Cyclic GMP-AMP synthase (cGAS) connects genome instability caused by platinum-based chemotherapeutics to type I interferon (IFN) response. Here, by using a high-throughput small-molecule microarray-based screening of cGAS interacting compounds, we identify brivanib, known as a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor, as a cGAS modulator. Brivanib markedly enhances cGAS-mediated type I IFN response in tumor cells treated with platinum. Mechanistically, brivanib directly targets cGAS and enhances its DNA binding affinity. Importantly, brivanib synergizes with cisplatin in tumor control by boosting CD8+ T cell response in a tumor-intrinsic cGAS-dependent manner, which is further validated by a patient-derived tumor-like cell clusters model. Taken together, our findings identify cGAS as an unprecedented target of brivanib and provide a rationale for the combination of brivanib with platinum-based chemotherapeutics in cancer treatment. Display omitted •High-throughput screening identifies brivanib as a cGAS activity-enhancing compound•Brivanib targets cGAS to boost its activation by enhancing its DNA binding affinity•Brivanib enhances platinum-induced type I IFN responses in tumor cells•Brivanib and cisplatin synergistically control tumors by boosting CD8+ T cell Liu et al. identify brivanib as a cGAS activity-enhancing compound and provide a proof-of-concept for sensitizing platinum-based chemotherapy by boosting cGAS-mediated antitumor immunity. Brivanib may serve as a drug candidate for sensitizing platinum-based chemotherapeutics in cancer treatment and intervention of cGAS-related diseases.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.